Pharmasight
Sign inSee a worked packBook the bench
Build · Iktos

Collaboration to develop next-generation HDAC inhibitors for non-oncological diseases (Jun 2024

ItalfarmacoBuildIktos

Italfarmaco collaboration to develop next-generation HDAC inhibitors for non-oncological diseases (Jun 2024.

Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.

Source

Published by Iktos on its own site — read the original case study on iktos.ai ↗

More like this

Related use cases

  1. 01Integrated drug-discovery collaboration (Jan 2026Pierre Fabre LaboratoriesIktosBuild
  2. 02Multi-target strategic collaboration, potential deal value >€1B (Jan 2026ServierIktosBuild
  3. 03Novel small-molecule amylin-receptor agonists for obesity, diabetes, cardiometabolic disease (Jan 2025Cube BiotechIktosBuild
  4. 04Partnership combining Reaxys chemistry database with Iktos AI for a predictive retrosynthesis platform (Mar 2024ElsevierIktosBuild
  5. 05Iktos AI de novo design applied to select Pfizer small-molecule discovery programs (2021PfizerIktosBuild
  6. 06Additional AI-for-new-drug-design collaboration (Nov 2020Merck KGaA, DarmstadtIktosBuild